SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is dominating conversations following reports of record-breaking vehicle deliveries for December and the fourth quarter, fueling strong community speculation about the company achieving its first profitable quarter. The electric vehicle maker's performance, alongside extended government subsidies for new energy vehicles in China, is generating bullish sentiment regarding its growth trajectory and competitive position against rivals. Despite some investor concern about market volatility, many remain focused on NIO's operational advancements.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is actively trending after a competitor's Cushing's syndrome treatment received a regulatory decline, clearing a significant market hurdle for Xeris's approved drug, Recorlev. The community is buzzing about this as a massive tailwind, expecting substantial market share gains that bolster XERS's already strong financial performance and promising pipeline. Analysts are reflecting this positive outlook, highlighting the company's compelling growth trajectory.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems (OSS) is trending due to the definitive sale of its Bressner Technology subsidiary for $22.4 million, a strategic move by management to focus on its higher-growth Edge AI compute business and strengthen its balance sheet. The community is actively discussing this, alongside strong anticipation for an imminent multi-hundred-million dollar US Army situational awareness contract, seeing OSS as significantly undervalued within the defense and AI sectors.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is drawing significant attention following robust Q3 earnings and strategic moves to bolster its ETF business through acquisitions, alongside its prominent role in a rebounding M&A market. The community is actively discussing the stock's impressive run and strategic AI integration efforts, with many anticipating continued strength, while others debate its high valuation and the potential for a stock split.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending sharply higher following the FDA's acceptance of its sNDA for AXS-05 in Alzheimer's disease agitation with Priority Review, setting a PDUFA target in April 2026. This significant regulatory clarity, coupled with positive updates for AXS-12 in narcolepsy and continued strong Auvelity script growth, is fueling widespread optimism among investors. The community is celebrating substantial long-term gains and actively discussing AXSM's potential to become a major CNS powerhouse, anticipating further analyst upgrades and robust performance as the company advances its diverse pipeline and commercial footprint.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bear 3X Shares

LABD, a leveraged inverse biotech ETF, is trending as the underlying XBI index continues an unexpected and sustained rally. This upward momentum, frequently attributed to recent sector buyouts and broader market sentiment regarding potential rate cuts, is causing significant frustration and deep losses for investors betting against the sector despite extreme overbought conditions.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is trending following mixed interim Phase 2 results for its ARCT-032 cystic fibrosis therapy, which showed signs of mucus plug reduction but limited lung function improvement, leading to significant stock volatility. Community sentiment is divided, with many viewing the sharp decline as an overreaction and highlighting the therapy's biological activity, the strength of their mRNA platform, other pipeline assets, and a high-stakes trade secret lawsuit against AbbVie as key discussion points for future value. Simultaneously, discussions around their influenza vaccine candidates are gaining traction amidst concerns over emerging flu variants.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

SMCX is trending as its community grapples with the impact of a recent dividend distribution, leading to widespread confusion and frustration over its sharp decline. Many investors are questioning why the 2x leveraged ETF is not tracking its underlying asset, SMCI, as expected, fueling concerns about decay and the potential for a reverse split. While some traders see the current suppressed levels as a buying opportunity, others warn of the significant volatility and risks inherent in such leveraged products.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending amidst intense community debate around its price trajectory as the year concludes. While many express significant frustration over sustained losses and question its future, a strong contingent remains optimistic, urging others to 'buy the dip' and anticipate a substantial rebound in the upcoming year. Discussions also highlight year-end tax selling and the impact of a recent Doge giveaway, adding to its current volatility.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending after its relacorilant drug for Cushing's syndrome received a Complete Response Letter from the FDA, requesting additional efficacy evidence despite a successful pivotal trial, causing a sharp stock decline. Many investors view this over 50% drop as an overreaction, highlighting the company's established, revenue-generating drug Korlym and its broader pipeline. Amidst year-end tax-loss selling and wider biotech sector volatility, community discussion centers on the potential for regulatory resolution versus further valuation adjustments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mayukh Sukhatme Sells 1,018,995 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) insider Mayukh Sukhatme sold 1,018,995 shares of the company's stock in a transaction that occurred on Wednesday, December 31st. The shares were...

Mayukh Sukhatme Sells 311,873 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) insider Mayukh Sukhatme sold 311,873 shares of Roivant Sciences stock in a transaction on Monday, December 29th. The shares were sold at an...

Short Interest in Roivant Sciences Ltd. (NASDAQ:ROIV) Drops By 16.2%

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) was the recipient of a significant drop in short interest during the month of December. As of December 15th, there was short interest totaling...

Insider Selling: Roivant Sciences (NASDAQ:ROIV) CEO Sells 75,000 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 75,000 shares of the business's stock in a transaction dated Wednesday, December 24th. The shares were sold at an average...

Eric Venker Sells 200,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the firm's stock in a transaction dated Tuesday, December 23rd. The stock was sold at an average price of...

Richard Pulik Sells 406,731 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CFO Richard Pulik sold 406,731 shares of Roivant Sciences stock in a transaction on Tuesday, December 23rd. The stock was sold at an average...

Capricorn Fund Managers Ltd Buys New Stake in Roivant Sciences Ltd. $ROIV

Capricorn Fund Managers Ltd purchased a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and...

Voya Investment Management LLC Grows Stock Position in Roivant Sciences Ltd. $ROIV

Voya Investment Management LLC lifted its position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 1,076.2% during the third quarter, according to its most recent Form 13F filing with the...

Insider Action: Multimillion-dollar sell-offs across major U.S. companies

CNBC's Frank Holland tracks insider selling confirmed by SEC filings, with major sales at Las Vegas Sands, Roivant Sciences, Nvidia, and Viasat, as executives and board members unload millions in...

Roivant Sciences (NASDAQ:ROIV) Insider Mayukh Sukhatme Sells 26,831 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) insider Mayukh Sukhatme sold 26,831 shares of Roivant Sciences stock in a transaction that occurred on Wednesday, December 17th. The shares were...

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Current Price	$21.70
Prev Close	$21.63
Open	$21.63
Dividend Yield	0.00%
50-Day Moving Average	$20.65
Beta	0.86
Avg. Volume	7.88M
PE Ratio	-39.27

52-Week High	$23.47
52-Week Low	$8.73
Market Capitalization	$15.04B
EPS (Annual)	-$0.2371
Price to Book	3.43
Revenue Per Employee	$38,737.33
Enterprise Value/EBITDA	N/A

ROIV
Roivant Sciences Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ROIV News

ROIVRoivant Sciences Ltd